Skip to main content

Advertisement

SpringerLink
Log in

Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To assess the changes in intraocular pressure (IOP) after intravitreal aflibercept injections in Japanese patients with neovascular age-related macular degeneration (nAMD) complicated by glaucoma.

Study design

Retrospective observational study.

Methods

We retrospectively reviewed 27 eyes of 25 Japanese patients diagnosed with nAMD complicated by glaucoma. The patients were treated with 2 mg/0.05 ml of aflibercept and followed for 52 weeks according to a treat-and-extend (TAE) regimen after 3 consecutive monthly injections. The IOP of each eye was measured at each visit using non-contact tonometry. IOP changes as well as additional glaucoma treatments during 52 weeks were recorded.

Results

The mean of aflibercept injections was 8.3 ± 1.9. The mean IOP at baseline was 14.0 ± 3.1 mmHg, and the mean IOP after aflibercept therapy was 13.0 ± 2.4 mmHg at the final visit (P = 0.0463). No patients received additional glaucoma treatment of eye drops or surgery.

Conclusion

Our results suggest that intravitreal aflibercept injections may be beneficial for patients with nAMD complicated by glaucoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Congdon N. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–85.

    Article  PubMed  Google Scholar 

  2. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153:209–13.

    Article  PubMed  Google Scholar 

  3. Jonas JB, Cheung CMG, Panda-Jonas S. Updates on the epidemiology of age-related macular degeneration. Asia-Pac J Ophthalmol. 2017;6:493–7.

    Google Scholar 

  4. Barash A, Chui TYP, Garcia P, Rosen RB. Acute macular and peripapillary angiographic changes with intravitreal injections. Retina. 2020;40:648–56.

    Article  PubMed  Google Scholar 

  5. Abedi G, Adelman RA, Salim S. Incidence and management of elevated intraocular pressure with anti-vascular endothelial growth factor agents. Sem Ophthalmol. 2013;28:126–30.

    Article  Google Scholar 

  6. Achiron A. Intraocular pressure spikes following neodymium-doped yttrium aluminum garnet laser capsulotomy: Current prevalence and management in Israel. J Curr Glaucoma Pract. 2017;11:63–6.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Baek SK, Kim JH, Kim JW, Kim CG. Increase in the population of patients with neovascular age-related macular degeneration who underwent long-term active treatment. Sci Rep. 2019;9:1–10.

    Article  Google Scholar 

  8. Dedania VS, Bakri SJ. Sustained elevation of intraocular pressure after intravitreal anti-vegf agents: what is the evidence? Retina. 2015;35:841–58.

    Article  CAS  PubMed  Google Scholar 

  9. Wehrli SJ, Tawse K, Levin MH, Zaidi A, Pistilli M, Brucker AJ. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina. 2012;32:1295–301.

    Article  CAS  PubMed  Google Scholar 

  10. Kim D, Nam WH, Kim HK, Yi K. Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure? J Glaucoma. 2014;23:446–8.

    Article  PubMed  Google Scholar 

  11. Nariani A, Williams B, Hariprasad S. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure. Indian J Ophthalmol. 2016;64:643–7.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology. 2015;122:1802–10.

    Article  PubMed  Google Scholar 

  13. Gabrielle P-H, Nguyen V, Wolff B, Essex R, Young S, Hunt A, et al. Intraocular pressure changes and vascular endothelial growth factor inhibitor use in various retinal diseases: long-term outcomes in routine clinical practice: data from the Fight Retinal Blindness! Registry. Ophthalmol Retina. 2020;4:861–70.

    Article  PubMed  Google Scholar 

  14. Maruyama-Inoue M, Inoue T, Mohamed S, Kitajima Y, Ikeda S, Ito A, et al. Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration. Sci Rep. 2021;11:1–5.

    Article  Google Scholar 

  15. Novais EA, Baumal CR, Sarraf D, Freund KB, Duker JS. Multimodal imaging in retinal disease: a consensus definition. Ophthalmic Surg Lasers Imaging Retina. 2016;47:201–6.

    Article  PubMed  Google Scholar 

  16. Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2014;158:313–27.

    Article  Google Scholar 

  17. Rusu I, Deobhakta A, Yoon D, Lee M, Slakter J, Klancnik J, et al. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments. Retina. 2014;34:2161–6.

    Article  CAS  PubMed  Google Scholar 

  18. Ramsey DJ, McCullum JC, Steinberger EE. Intraocular pressure decreases in eyes with glaucoma-related diagnoses after conversion to aflibercept for treatment-resistant age-related macular degeneration. Eye (Lond). 2022;36:1813–9.

    Article  CAS  PubMed  Google Scholar 

  19. Stein JD, Kim DS, Niziol LM, Talwar N, Nan B, Musch DC, et al. Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. Ophthalmology. 2011;118:1031–7.

    Article  PubMed  Google Scholar 

  20. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79.

    Article  PubMed  Google Scholar 

  21. Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Basingstoke). 2018;32:1010–20.

    CAS  Google Scholar 

  22. Van Bergen T, Jonckx B, Hollanders K, Sijnave D, Van de Velde S, Vandewalle E, et al. Inhibition of placental growth factor improves surgical outcome of glaucoma surgery. J Cell Mol Med. 2013;17:1632–43.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Van Bergen T, Etienne I, Cunningham F, Moons L, Schlingemann RO, Feyen JHM, et al. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. Prog Retin Eye Res. 2019;69:116–36.

    Article  PubMed  Google Scholar 

  24. Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda D, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Fukushima Medical University, 1-Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan

    Junichiro Honjo, Ryo Mukai, Kanako Itagaki, Keiichiro Tanaka, Koki Norikawa, Yutaka Kato, Akihito Kasai, Yukinori Sugano & Tetsuju Sekiryu

Authors
  1. Junichiro Honjo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryo Mukai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kanako Itagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keiichiro Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koki Norikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yutaka Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akihito Kasai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yukinori Sugano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tetsuju Sekiryu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tetsuju Sekiryu.

Ethics declarations

Conflicts of interest

J. Honjo, None; R. Mukai, None; K. Itagaki, None; K. Tanaka, None; K. Norikawa, None; Y. Kato, None; A. Kasai, None; Y. Sugano, None; T. Sekiryu, None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Corresponding Author: Tetsuju Sekiryu

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 88 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Honjo, J., Mukai, R., Itagaki, K. et al. Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma. Jpn J Ophthalmol 68, 91–95 (2024). https://doi.org/10.1007/s10384-023-01041-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-023-01041-3

Keywords

Search

Navigation